PMC:7283670 / 61539-62209 JSONTXT

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T574","span":{"begin":34,"end":38},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"},{"id":"T575","span":{"begin":51,"end":53},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T576","span":{"begin":97,"end":101},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"},{"id":"T577","span":{"begin":114,"end":116},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T578","span":{"begin":623,"end":627},"obj":"http://purl.obolibrary.org/obo/CLO_0053799"}],"text":"Primary: viral load (hospital Day 3, 5, 7, 10, 14, 18)\nSecondary viral load change (hospital Day 3, 5, 7, 10, 14, 18), time to clinical improvement (time frame: up to 28 days), percentage of progression to supplemental oxygen requirement by Day 7, Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hr by Day 7, time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission (up to 28 days), rate of switch to lopinavir/ritonavir or hydroxychloroquine by Day 7, adverse effects (up to 28 days), concentration of lopinavir/ritonavir and hydroxychloroquine (1, 2, 4, 5, 12 hr after taking intervention medicine)"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T71387","span":{"begin":219,"end":225},"obj":"Chemical"},{"id":"T58068","span":{"begin":471,"end":490},"obj":"Chemical"},{"id":"T12331","span":{"begin":471,"end":480},"obj":"Chemical"},{"id":"T50748","span":{"begin":481,"end":490},"obj":"Chemical"},{"id":"T149","span":{"begin":494,"end":512},"obj":"Chemical"},{"id":"T150","span":{"begin":573,"end":592},"obj":"Chemical"},{"id":"T151","span":{"begin":573,"end":582},"obj":"Chemical"},{"id":"T152","span":{"begin":583,"end":592},"obj":"Chemical"},{"id":"T153","span":{"begin":597,"end":615},"obj":"Chemical"},{"id":"T154","span":{"begin":661,"end":669},"obj":"Chemical"}],"attributes":[{"id":"A38777","pred":"chebi_id","subj":"T71387","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A20970","pred":"chebi_id","subj":"T58068","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A27687","pred":"chebi_id","subj":"T12331","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A95323","pred":"chebi_id","subj":"T50748","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A149","pred":"chebi_id","subj":"T149","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A150","pred":"chebi_id","subj":"T150","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A151","pred":"chebi_id","subj":"T151","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A152","pred":"chebi_id","subj":"T152","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A153","pred":"chebi_id","subj":"T153","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A154","pred":"chebi_id","subj":"T154","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"Primary: viral load (hospital Day 3, 5, 7, 10, 14, 18)\nSecondary viral load change (hospital Day 3, 5, 7, 10, 14, 18), time to clinical improvement (time frame: up to 28 days), percentage of progression to supplemental oxygen requirement by Day 7, Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hr by Day 7, time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission (up to 28 days), rate of switch to lopinavir/ritonavir or hydroxychloroquine by Day 7, adverse effects (up to 28 days), concentration of lopinavir/ritonavir and hydroxychloroquine (1, 2, 4, 5, 12 hr after taking intervention medicine)"}

{"project":"LitCovid-PubTator","denotations":[{"id":"2059","span":{"begin":471,"end":490},"obj":"Chemical"},{"id":"2060","span":{"begin":573,"end":592},"obj":"Chemical"},{"id":"2124","span":{"begin":388,"end":393},"obj":"Disease"}],"attributes":[{"id":"A2059","pred":"tao:has_database_id","subj":"2059","obj":"MESH:C558899"},{"id":"A2060","pred":"tao:has_database_id","subj":"2060","obj":"MESH:C558899"},{"id":"A2124","pred":"tao:has_database_id","subj":"2124","obj":"MESH:D003643"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Primary: viral load (hospital Day 3, 5, 7, 10, 14, 18)\nSecondary viral load change (hospital Day 3, 5, 7, 10, 14, 18), time to clinical improvement (time frame: up to 28 days), percentage of progression to supplemental oxygen requirement by Day 7, Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hr by Day 7, time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission (up to 28 days), rate of switch to lopinavir/ritonavir or hydroxychloroquine by Day 7, adverse effects (up to 28 days), concentration of lopinavir/ritonavir and hydroxychloroquine (1, 2, 4, 5, 12 hr after taking intervention medicine)"}